Patrick Campbell

In our nephrology month in review for May 2024, we spotlight the biggest news from the NKF and ERA meetings, including the latest updates in IgA nephropathy, C3 glomerulopathy, chronic kidney disease, and more!

Our cardiology month in review spotlights the top 5 storylines that defined cardiology during May 2024, including new HCM guidelines, news from ESA 2024, and the FLOW trial.

Announced on May 29, 2024, data from the MDD3001 trial indicate use of seltorexant was associated with meaningful improvements in depressive symptoms and sleep disturbances.

Robert Rosenson, MD, discusses the results of the ARCHES-2 trial and how it informs the potential of ANGPTL3 inhibition as well as RNAi therapies.

Robert Rosenson, MD, discusses the unmet need in mixed hyperlipidemia and the potential for RNA interference therapies in this patient population.

A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.

The FDA approved eculizumab-aeeb (Bkemv) as an interchangeable biosimilar to eculizumab (Soliris) for treating PNH and aHUS, marking the agency’s 53rd biosimilar approval.

Relacorilant achieves primary endpoint in phase 3 GRACE trial among patients with hypercortisolism and hyperglycemia, hypertension or both, with sNDA expected in Q3 2024.

Jonathan Barratt, MD, discusses a matching-adjusted indirect comparison of sparsentan and irbesartan against standard of care plus optimized RASI.

An analysis of more than 800 IgAN patients treated from 2002-2021 provides an overview of factors associated with anemia as well as its impact on prognosis.

Fadi Fakhouri, MD, PhD, discusses the 1-year results of the NOBLE trial examining use of pegcetacoplan in patients with post-transplant C3G or IC-MPGN.

A phase 2b dose-finding study suggests use of clazakizumab was associated with a reduction in hs-CRP among patients undergoing maintenance dialysis.

Jonathan Barratt, MD, discusses the 52-week data from the phase 1/2 trial of zigakibart, which was presented at the 61st European Renal Association Congress.

A Q&A with David Kavanagh, MBChB, PhD, on the results of the APPEAR-C3G trial and implications for care moving forward.

The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.

In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.

Helen Colhoun, MD, discusses the results of a SELECT analysis she presented at the 61st European Renal Association Congress.

Semaglutide 2.4 mg reduces kidney events in SELECT participants, showing renoprotective effects in addition to cardiovascular benefits.

Circulating antinephrin autoantibodies identified as reliable biomarkers for MCD and primary FSGS, enhancing diagnostic precision and monitoring of nephrotic syndromes.

Data from ERA 24 builds on previous research examining the effect of SGLT2 inhibitors on hemoglobin levels among patients with chronic kidney disease.

Hear from Katharina Mayer, MD, and Georg Böhmig, MD, on the results of the phase 2 trial of felzartamab in patients with antibody-mediated rejection following kidney transplantation.

Atrasentan significantly reduces proteinuria in patients with IgA nephropathy, showing a 36.1% reduction compared to placebo at 36 weeks.

Study finds roxadustat effectively treats anemia in both dialysis-dependent and non-dialysis-dependent CKD patients.

Vlado Perkovic, MBBS, PhD, discusses the results of the FLOW trial and their implications for clinical practice at ERA 24.

New study finds SGLT2 inhibitors reduce proteinuria in IgA nephropathy, with greater initial eGFR dips predicting stronger treatment responses.

Semaglutide 1.0 mg reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease, according to the FLOW trial.

Increases in metabolic risk factors like high blood pressure and BMI have led to a 49.4% increase in global disability-adjusted life years from 2000 to 2021.

A recent study suggests that high ultraprocessed food consumption in preschool children is linked to increased cardiometabolic risk factors.

On May 20, 2024, the FDA announced the approval of 2 products as interchangeable biosimilars to aflibercept—the first products to receive such a designation from the FDA.

Use of dupilumab reduced exacerbations and improved lung function in COPD patients with type 2 inflammation.